lactobacillus brevis

Cell therapyexperimental

Levilactobacillus brevis is a gram-positive, rod shaped species of lactic acid bacteria which is heterofermentative, creating CO2, lactic acid and acetic acid or ethanol during fermentation. L. brevis is the type species of the genus Levilactobacillus (previously L. brevis group), which comprises 24 species. It can be found in many different environments, such as fermented foods, and as normal microbiota. L. brevis is found in food such as sauerkraut and pickles. It is also one of the most common causes of beer spoilage. Ingestion has been shown to improve human immune function, and it has been patented several times. Normal gut microbiota L. brevis is found in human intestines, vagina, and feces. — Wikipedia

Clinical trial activity

20 trials · 32 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
10
Phase 3
8
Phase 4
2

Earliest trial started Feb 1, 2006 (NCT00587041)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • inersan
  • lactobacillus brevis
  • lactobacillus brevis cd2
  • l. brevis
  • l. brevis cd2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04823676N/AMar 31, 2021AB Biotics, SA
NCT04366089Phase 2Mar 26, 2020University of Roma La Sapienza
NCT03959722N/AOct 31, 2019Hogeschool Leiden, University of Applied Sciences, Leiden University, University of Amsterdam, Wageningen University, Winclove Bio Industries BV
NCT04398511Phase 2Jan 7, 2019Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Universidade de Passo Fundo
NCT04089280N/AOct 16, 2018Sanprobi Sp. z o.o., Silesian University of Medicine
NCT03540498N/AOct 13, 2016AB Biotics, SA, University of Barcelona
NCT04203771N/AJun 30, 2016AB Biotics, SA, University of Barcelona
NCT02357771Phase 3Apr 1, 2015Next Gen Pharma India Pvt. Ltd., Peoples College of Dental Sciences & Research Centre, Bhanpur, Bhopal, Madya Pradesh, Peoples University, Bhanpur, Bhopal
NCT02329353Phase 3Feb 1, 2015Krishnadevaraya College of Dental Sciences & Hospital, Next Gen Pharma India Pvt. Ltd.
NCT02203812Phase 3Jan 1, 2015CD Pharma India Pvt. Ltd., Government Dental College and Hospital, Vijayawada, Andhra Pradesh
NCT02174757Phase 3Aug 1, 2014CD Pharma India Pvt. Ltd., Sree Mookambika Institute of Dental Sciences
NCT02121665Phase 3Jul 1, 2014CD Pharma India Pvt. Ltd., Government Dental College & Hospital, Aurangabad
NCT02085694Phase 2/Phase 3 (Phase 3)Mar 1, 2014Catholic University of Sacred Heart, Rome
NCT01870362Phase 3Jun 1, 2013CD Pharma India Pvt. Ltd., Mahatma Gandhi Post-Graduate Institute of Dental Sciences
NCT01778699Phase 4Feb 1, 2013University of Gothenburg, University of Milan, University of Sassari
NCT01782079N/AJan 1, 2013University of Roma La Sapienza
NCT01707641Phase 4Nov 1, 2012University of Roma La Sapienza
NCT01545687Phase 3Apr 1, 2012Mayo Clinic, National Cancer Institute (NCI)
NCT01438333N/ASep 1, 2011University of L'Aquila
NCT00587041Phase 1/Phase 2 (Phase 2)Feb 1, 2006Mayo Clinic, National Center for Complementary and Integrative Health (NCCIH), National Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH)
Showing 20 of 20 trials
Page 1 / 1

Organizations